NCT02507167

Impact of Two Genetic Variants of OATP1B3 or MRP2 or Rifampin on Systemic Disposition and Biological Efficacy of CCK-8

Impact of Two Genetic Variants of OATP 1B3 or MRP 2 or Rifampin Mediated Transporter Inhibition on Systemic Disposition and Biological Efficacy of CCK-8 in 36 Healthy Male Individuals

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: University Medicine Greifswald · Academic / Other
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the impact of genetic variants of OATP 1B3 or MRP 2 on the systemic disposition of endogenously formed CCK-8 and to determine the influence of a single-dose of the transporter inhibitor rifampin (600 mg) on the systemic disposition of endogenously formed CCK-8. Endogenous CCK-8 secretion will be induced by a single-dose standardized liquid mixed meal.

Conditions

• Gastrointestinal Hormones

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	mixed meal	250 ml Fortimel compact (chocolate)
DRUG	Rifampin	oral rifampin administration (600 mg EREMFAT®)

Timeline

• Start date: 2012-11-01
• Primary completion: 2013-07-01
• Completion: 2014-12-01
• First posted: 2015-07-23
• Last updated: 2015-07-23

Locations

1 site across 1 country: Germany